Abstract: A method, a device and a storage medium for evaluating speech quality include: receiving speech data to be evaluated; extracting evaluation features of the speech data to be evaluated; performing quality evaluation to the speech data to be evaluated according to the evaluation features of the speech data to be evaluated and a predetermined speech quality evaluation model, in which the speech quality evaluation model is an indication of a relationship between evaluation features of single-ended speech data and quality information of the single-ended speech data.

Abstract: A method for recognizing a character includes: obtaining a character; converting the character into a radical based character recognition result, where the radical based character recognition result comprises symbols indicating radicals of the character and a structure of the radicals of the character; and recognizing the character based on the radical based character recognition result.

Abstract: Disclosed in the present application are a class of compounds as JAK inhibitors and use thereof in the preparation of medicaments for treating JAK and TYK2 related diseases. Specifically, a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof is disclosed.

Abstract: An echo cancellation method based on delay estimation is provided. In the method, a microphone signal and a reference signal are received and preprocessed. In the preprocessed microphone signal and the preprocessed reference signal, frequency point signals with non-linearity in a current echo cancellation scenario are determined. A current delay estimation value is calculated based on frequency point signals without non-linearity in the microphone signal and the reference signal. The reference signal is shifted based on the current delay estimation value. An adaptive filter is updated based on the preprocessed microphone signal and the shifted reference signal, to perform echo cancellation.

Abstract: A target voice detection method and a target voice detection apparatus are provided. The method includes: receiving sound signals collected by a microphone array; performing a beamforming process on the sound signals to obtain beams in different directions; extracting a detection feature of each frame based on the sound signals and the beams in different directions; inputting an extracted detection feature of a current frame into a pre-constructed target voice detection model to obtain a model output result; and obtaining a target voice detection result of the current frame based on the model output result.

Abstract: A microphone array-based target voice acquisition method and device, said method comprising: receiving voice signals acquired on the basis of a microphone array (101); determining a pre-selected target voice signal and a direction thereof (102); performing strong directional gain and weak directional gain on the pre-selected target voice signal, so as to obtain a strong gain signal and a weak gain signal (103); performing an endpoint detection on the basis of the strong gain signal, so as to obtain an endpoint detection result (104); and performing endpoint processing on the weak gain signal according to the endpoint detection result, so as to obtain a final target voice signal (105). The present invention can obtain an accurate and reliable target voice signal, thereby avoiding an adverse effect of the target voice quality on subsequent target voice processing.

Abstract: Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

Abstract: The present application relates to a crystal of a tricyclic compound, in particular to a crystal of (S)-8-(4,4-difluorocyclohexyl)-8H-thieno[3,4]pyrrolo[1,5-a]imidazole, a preparation method therefor, a crystal composition and a pharmaceutical composition thereof and the use thereof. The X-ray powder diffraction spectrum of the crystal of the compound of formula I in the present application, represented by a 2? value, has a diffraction peak at about 11.49°, 15.05°, 20.14°, 21.53° or 21.79°. The crystal of the compound of formula I in the present application has excellent physical properties, high safety and metabolic stability, and has a good inhibitory effect on IDO and a high medicinal value.

Abstract: Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof.

Abstract: A method, an apparatus and a device for converting a whispered speech, and a readable storage medium are provided. The method is implemented based on the whispered speech converting model. The whispered speech converting model is trained in advance by using recognition results and whispered speech training acoustic features of whispered speech training data as samples and using normal speech acoustic features of normal speech data parallel to the whispered speech training data as sample labels. A whispered speech acoustic feature and a preliminary recognition result of whispered speech data are acquired, then the whispered speech acoustic feature and the preliminary recognition result are inputted into a preset whispered speech converting model to acquire a normal speech acoustic feature outputted by the model. In this way, the whispered speech can be converted to a normal speech.

Abstract: Provided are a PDE4 inhibitor and a use thereof in the preparation of a medicament for treating PDE4 related diseases. Specifically disclosed are the compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

Abstract: The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same.

Abstract: A method for recognizing a character includes: obtaining a character; converting the character into a radical based character recognition result, where the radical based character recognition result comprises symbols indicating radicals of the character and a structure of the radicals of the character; and recognizing the character based on the radical based character recognition result.

Abstract: Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to A2A receptor. The R1, R2, R3, ring A, ring B, n, and m are as defined in the specification.

Abstract: The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.

Abstract: Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.

Abstract: A benzotriazole-derived ? and ?-unsaturated amide compound used as TGF-?R1 inhibitor or a pharmaceutically acceptable salt thereof, the structure of the compound being as shown in formula (I).

Abstract: Provided are a phosphodiesterase-4 (PDE4) inhibitor and application thereof in preparation of a medication for treating a disease related to PDE4. Specifically disclosed is a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.